Skip to main content
. Author manuscript; available in PMC: 2013 Dec 5.
Published in final edited form as: Chembiochem. 2010 Jul 26;11(11):10.1002/cbic.201000222. doi: 10.1002/cbic.201000222

Figure 3.

Figure 3

The two-headed PROTAC (5) induces degradation of the ER in a proteasome-dependent manner. A. Co-treatment of cells with the PROTAC (5, 10 μM)and a proteasome inhibitor (0, 100 and 500 nM of epoxomicin) over 48 hours blocks the PROTAC-mediated degradation of the ER. E2 (10 nM) plus inhibitor is included as a positive control. B. Immunofluorescent images of MCF-7 cells treated as in 3A where the green color indicates the ER and the blue color (DAPI) indicates the nucleus. ER degradation is seen in (5) when compared to control, while co-treatment of (5) with epoxomicin (100 nM) caused accumulation of the ER.